Hoyland or anyone else- what are your thoughts about Benitec doing a potential sub-license agreement with Regenxbio to sell our silence & replace vector technology to their existing customer base?
Below is a Barron's article quote regarding Regenxbio partnerships & royalties...
"Amusa, the Chardan analyst, favors Regenxbio, calling it “the best way to broadly play the emergence of vector-based gene therapy.” The company, based in Rockville, Md., is licensing viral vectors to about 10 partners, including AveXis and Audentes, and will get royalties estimated at about 10% if those treatments are commercialized."
Regenxbio could be an efficient route for Benitec to sell it's silence & replace expertise tech to multiple partners quickly because of Regenxbio established partnerships with many biotech companies..
- Forums
- ASX - By Stock
- BLT
- Silence & Replace Sub-licence
Silence & Replace Sub-licence
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)